Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-25-062743
Filing Date
2025-05-02
Accepted
2025-05-02 16:05:04
Documents
4
Period of Report
2025-06-27

Document Format Files

Seq Description Document Type Size
1 PRE 14A ikt-20250502.htm PRE 14A 1078869
2 GRAPHIC img37485347_0.jpg GRAPHIC 80488
3 GRAPHIC img37485347_1.jpg GRAPHIC 501767
4 GRAPHIC img37485347_2.jpg GRAPHIC 238975
  Complete submission text file 0000950170-25-062743.txt   2207024
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-39676 | Film No.: 25908395
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)